Dealbreaker on MSN5 小时
Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity
Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million.
bluebird bio stock slides for second day on buyout news
Shares of bluebird bio (NASDAQ:BLUE) continued their downward descent Monday in the wake of news that the company has been agreed to be taken private by Carlyle Group (NASDAQ:CG) and SK Capital ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Bluebird Bio price target lowered to $5 from $40 at Wells Fargo
Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Bluebird Bio (BLUE) to $5 from $40 and keeps an Equal Weight rating on the ...
pharmaphorum15 小时
Troubled gene therapy player bluebird sold for a song
12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...
The Pharma Letter15 小时
The week in pharma: action, reaction and insight – week to February 21
Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...
红板报 on MSN19 小时
蓝鸟“消失”的那一夜
本文来自微信公众号：氨基观察，作者：郑晓，题图来自：Bluebird Bio 创新药企创业，成功是小概率事件，失败、消失是最常见的结局。 过去 20 多年的 biotech ...
创新药明星坠落：蓝鸟“消失”的那一夜
蓝鸟因为超前的基因疗法而闻名，率先成功上岸成为先驱，但基因疗法的创新性，导致安全性问题拖延商业化节奏，又因为价格问题导致变现困难…… 一系列因素让蓝鸟持续失血，最终无力回天。